16th May 2024

Closed Loop Medicine and Pharmanovia commence study for their first precision medicine combination therapeutic

PRESS RELEASE: For global business and medical media only 16 May 2024

Closed Loop Medicine and Pharmanovia commence OptiZest study for their first precision medicine combination therapeutic

  • Proof-of-Concept study to investigate personalized dose management of first-line anti-hypertensive in improving blood pressure control remotely
  • Key milestone in co-development partnership to combine leading medicine brands with dose optimization technology to advance patient care quality across diverse therapeutic areas

London and Basildon, UK, Please note strict embargo, not to be published or broadcast before 9AM BST 16 May 2024: Closed Loop Medicine Ltd, a leading TechBio company developing combination prescription drug plus software therapy products that deliver personalized dose optimization, and Pharmanovia, a global pharmaceutical company that commercializes novel medicines and revitalizes, extends and expands the lifecycle of established medicines, today announced the initiation of their OptiZest study, ID: NCT06372470, and first patient recruitment.

OptiZest will investigate whether patients with hypertension can improve blood pressure control at home while receiving a personalized dose of Zestril (lisinopril).  The study demonstrates an important stage in Closed Loop Medicine and Pharmanovia’s co-development partnership to progress the development and launch of a drug plus software combination version of a first-line anti-hypertensive in the UK, before phased global roll-out and additional therapeutic areas are added.

Hypertension is a leading preventable cause of morbidity and premature death worldwide, impacting over 1 in 4 men and 1 in 5 women, and costing the NHS alone over £2.1 billion/year (1, 2). Medication and lifestyle interventions have been shown to significantly reduce associated health risks and improve quality of life, however, poor drug tolerability and treatment-related side effects significantly impact adherence and overall disease management (3).

By combining Closed Loop Medicine’s proprietary Software-as-a-Medical Device (SaMD) dose optimization technology and Pharmanovia’s established medicine brands, the companies aim to support patients and healthcare professionals through the development of an innovative intervention. The partnership is initially focused on addressing the clinical need in hypertension, which builds on recent trial data demonstrating the ability of Closed Loop Medicine’s SaMD platform to successfully control blood pressure, minimize side effects, and support medication adherence in participants, when linked with another first-line anti-hypertensive (4).

OptiZest is co-funded by both companies and led by Dr. Serge Engamba, GP and Clinical Research Lead at North Norfolk Primary Care. The study is also being supported by the National Institute for Health and Care Research.

Dr. Serge Engamba, Chief Investigator of OptiZest, GP, Clinical Research Lead at North Norfolk Primary Care and Deputy Specialty Lead at NIHR CRN East of England, commented: “Persistent high blood pressure can increase your risk of a number of serious and potentially life-threatening health conditions, such as heart attacks, strokes, kidney disease and even dementia. It is therefore crucial that doctors and patients work together to achieve optimal management of this condition. This pioneering research study offers an unprecedented opportunity to understand how effectively we can do this using innovative technologies and well-known medicines.”

Dr. Hakim Yadi PhD OBE, CEO & Co-Founder, Closed Loop Medicine, said: “Our dedication to advancing the quality of patient care is exemplified through our partnership with Pharmanovia and the initiation of the OptiZest study. This not only represents a milestone in hypertension management, but also underscores our broader mission to support healthcare systems in improving patient outcomes across diverse therapeutic areas.”

Dr. James Burt, CEO of Pharmanovia, said:OptiZest speaks to the heart of what we’re trying to do at Pharmanovia, which is to advance healthcare by innovating established medicines; enabling clinicians to efficiently personalize treatments for patients and seek to optimize the balance between efficacy and unwanted side effects. Starting by delivering much needed innovation to hypertension management, this study sets the stage for development and launch of one of the first drug and software combination products for hypertension.”

  1. https://www.who.int/health-topics/hypertension
  2. https://ukhsa.blog.gov.uk/2017/01/24/health-matters-combating-high-blood-pressure/
  3. https://journalforclinicalstudies.com/revolutionising-hypertension-management-through-personalised-data-driven-dose-optimisation/
  4. Collier DJ et al. 2024.  https://www.ahajournals.org/doi/10.1161/JAHA.123.030749

ENDS

Notes to Editors:

For high-resolution images of James Burt, CEO Pharmanovia, Hakim Yadi CEO, CLM or Dr. Serge Engamba (Chief Investigator), Hattie Whiteside, Derick Fernandes (PCN Clinical
Pharmacists) for the OptiZest study

For further information please contact:

Pharmanovia

Alison Dyson, Director of Communications

Email: communications@pharmanovia.com

Tel: +44 (0) 07912887250

About Pharmanovia

Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.

We do this by commercializing novel medicines and technologies as well as rediscovering, repurposing or re-engineering established medicines to improve patient outcomes and experiences.

With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.

To learn more about Pharmanovia: www.pharmanovia.com/

About Closed Loop Medicine

Closed Loop Medicine is a TechBio company developing combination prescription drug plus software products, with the aim of bringing forward the promise of precision care. The Company’s proprietary technology platform facilitates personalized and optimized dosing, through integration of medicines and software with patient-led digital experiences and closed loop models of care. This approach to treating the individual, not just the disease, has the potential to provide bespoke universal healthcare access and improve outcomes for patients with chronic diseases.

Founded at the Babraham Institute in Cambridge, UK in 2017, and now based in London, UK, Closed Loop Medicine’s investors include Ananda Impact Ventures, BGF, LifeArc, Longwall, Meltwind, IQ Capital, Downing Ventures and Cambridge Angels.

To learn more about Closed Loop Medicine and its mission to deliver precision care for all, please visit: www.closedloopmedicine.com/

CLM Press release – COR2024PR00101